San Diego, CA, Nascent Biotech Inc (NBIO: OTC) announced today that it has recently closed a non-brokered private placement round for aggregate gross proceeds of $1.2Million.
Management raised funds and the use of Proceeds will be for developing antibodies used to treat cancer; including manufacturing, preparation for human clinical trials, general working capital and administration.
Sean Carrick, President of Nascent commented, “We were overwhelmed by the interest in our initial round. We chose to accept strategic money in this first round as we believe the right partners will prove to be more beneficial in the long run.”
About Nascent Biotech, Inc.
Nascent Biotech is building a portfolio of innovative therapeutic antibodies, poised at various stages of development, ranging from laboratory to the eve of clinical trials. Nascent Biotech is using and developing natural human antibodies and responses obtained from the innate natural human immune response as a drug discovery platform for identifying new antibodies and antigens for commercialization.
We encourage any interested parties to visit https://www.nascentbiotech.com/
Issued on behalf of the Board of Directors of Nascent Biotech Inc.
Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on October 28, 2014, and future filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Contact:
Nascent Biotech, Inc.
Sean Carrick
President
772.713.0541
sean.carrick@nascentbiotech.com
www.nascentbiotech.com
